Clinical Trial Update: Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% [NA]

View source ↗

Summary

This completed trial assessed topical loteprednol etabonate 0.5% for ocular graft-versus-host disease presenting with dry eyes; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eyes
• Graft-versus-host Disease

Drugs mentioned

• Loteprednol etabonate 0.5% ophthalmic suspension (Lotemax) (loteprednol etabonate)

Snippet

Sponsor: University of Michigan | Conditions: Dry Eyes | NA | Status: COMPLETED | Results posted: 2015-09-24